Moleculin Evaluates Prelim. Activity Of Annamycin In Acute Ara-C, VEN Resistant Myeloid Leukemia

(RTTNews) - Moleculin Biotech, Inc. (MBRX), Wednesday announced the preliminary activity of Annamycin in heavily pretreated, relapsed/refractory acute myeloid leukemia or AML patients who had progressive disease following cytarabine or Ara-C and Venetoclax or VEN.

The company said Annamycin effectively targeted both Ara-C and Venetoclax resistant AML cell lines in vitro.

The preclinical study recorded lack of apparent cardiotoxicity, improved organotropism, synergy with Ara-C, and possible immune-memory reinforcing properties.

The anti-leukemic efficacy of Annamycin in combination with Ara-C was evaluated in TP53 null FLT3-ITD mutated syngeneic AML Turqoise2 model, with evaluation of tumor burden in bone marrow, spleen, lungs, and liver by fluorescence imaging.

Moreover, the company is advancing the development of Annamycin in a Phase 3 pivotal trial evaluating AnnAraC for the treatment of AML patients who are refractory to or relapsed after induction therapy, with patient treatment expected to begin in the first quarter of 2025.

An abstract of the study was published as part of the American Society of Hematology Annual Meeting.

Currently, Moleculin's stock is moving up 13.26 percent, to $2.72 on the Nasdaq.